Dermatofibrosarcoma Protuberans
📧 Sign up to get email alerts when something new happens for Dermatofibrosarcoma Protuberans.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-06FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for Imatinib Mesylate (ANDA 212773), approving a generic version of the cancer…
-
EMA approval · 2026-03-05EMA Authorised: Imatinib Teva (imatinib) — Teva B.V.
EMA authorised Imatinib Teva (imatinib) for multiple indications including chronic myeloid leukemia, precursor cell lymphoblastic leukemia-l…
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
-
FDA approval · 2025-03-20FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate (Teva) under an ANDA, authorizing continued regulatory approval for this gener…
-
FDA approval · 2025-01-08FDA Approved: IMATINIB MESYLATE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental ANDA for Imatinib Mesylate (Chartwell RX, LLC), enabling marketing of a generic version of the cancer drug.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for imatinib mesylate from Mylan Pharmaceuticals, effectively authorizing a supplemental approva…
-
FDA approval · 2024-11-22FDA Approved: IMKELDI — Original Application (Shorla Oncology Inc.,)
FDA approved IMKELDI (imatinib oral) under an original NDA from Shorla Oncology, authorizing a new imatinib product for several cancers incl…
-
CLINICAL_TRIALS research · 2024-09-24Clinical Trial Update: NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique [Phase 1]
Phase 1 study update for NIFR image-guided surgery using a low-dose SWIG technique in malignant soft tissue tumors. The trial is not yet rec…
-
FDA approval · 2024-03-01FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation. This action confi…
-
FDA approval · 2024-01-05FDA Approved: IMATINIB MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for imatinib mesylate, enabling a generic version to be marketed under AN…
-
FDA approval · 2023-08-16FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for Imatinib from Dr. Reddy's Laboratories Inc, resulting in regulatory approval for a change to the…
-
FDA approval · 2023-01-31FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Imatinib Mesylate from BluePoint Laboratories under an ANDA, confirming approval of a generic pr…
-
FDA approval · 2022-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved an original application for imatinib mesylate (Upsher-Smith Laboratories) as a generic product. The approval supports its use f…
-
FDA approval · 2021-03-25FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for imatinib from Dr. Reddy's Laboratories, supporting an update to the drug's labeling under the AN…
-
FDA approval · 2020-08-10FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis, approving changes to the product labeling based o…
-
FDA approval · 2020-07-23FDA Approved: IMATINIB MESYLATE — Original Application (BluePoint Laboratories)
FDA approved imatinib mesylate as an original-application generic drug for BluePoint Laboratories.
-
FDA approval · 2020-01-09FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for imatinib mesylate from Teva Pharmaceuticals USA, Inc., under ANDA204285.
-
FDA approval · 2019-01-17FDA Approved: IMATINIB MESYLATE — Original Application (Chartwell RX, LLC)
FDA approves an original ANDA for imatinib mesylate, granting Chartwell RX, LLC a generic version (ANDA 208429).
-
FDA approval · 2018-08-13FDA Approved: IMATINIB — Original Application (Dr.Reddy's Laboratories Inc)
FDA approved the original application for imatinib from Dr. Reddy's Laboratories Inc, enabling the generic product to be marketed in the Uni…
-
FDA approval · 2017-09-29FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental NDA for GLEEVEC (imatinib mesylate) filed by Novartis Pharmaceuticals Corporation, resulting in changes to the p…
-
FDA approval · 2017-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original application for imatinib mesylate tablets, a generic version of Gleevec, for the same indications as the refer…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes [Phase 2]
Phase 2 clinical trial evaluating imatinib mesylate in patients with various activated tyrosine kinase-driven malignancies, including hypere…
-
FDA approval · 2016-08-25FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2016-08-17FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for imatinib mesylate, a generic version of the cancer drug, to update its approval status.
-
FDA approval · 2016-08-04FDA Approved: IMATINIB MESYLATE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approval of Teva's Imatinib Mesylate Original Application under ANDA204285 for a generic Imatinib product.